Literature DB >> 12379325

The epitope recognized by the unique anti-MUC1 monoclonal antibody MY.1E12 involves sialyl alpha 2-3galactosyl beta 1-3N-acetylgalactosaminide linked to a distinct threonine residue in the MUC1 tandem repeat.

Hideyuki Takeuchi1, Kentaro Kato, Kaori Denda-Nagai, Franz-Georg Hanisch, Henrik Clausen, Tatsuro Irimura.   

Abstract

The specificity of the MY.1E12 mAb that was generated by immunizing mice with human milk fat globule (HMFG) was investigated. Fluorescein isothiocyanate (FITC)-conjugated peptides corresponding to a portion of the MUC1 tandem repeat were enzymatically glycosylated with N-acetylgalactosamine, galactose, and then sialic acid. The MY.1E12 mAb was examined for its affinity to the resulting glycopeptides by fluorescence polarization. Its affinity for the peptide whose Thr within the VTS sequence bears a Neu5Ac alpha 2-3Gal beta 1-3GalNAc trisaccharide (K(d)=1.4 x 10(-7) M) was significantly higher than for the same peptide whose Thr bears an unsialylated disaccharide (K(d)=3.9 x 10(-6) M). The MY.1E12 mAb also bound strongly to a purified recombinant MUC1 fusion protein with six tandem repeats that was expressed by transfected MCF-7 breast cancer cells. The removal of sialic acids from the fusion protein significantly decreased MY.1E12 mAb reactivity, much more so than the MUC1-specific 115D8 antibody, whose epitope is known to be destroyed by desialylation. Thus, the attachment of the sialyl alpha 2-3Gal beta 1-3 beta 1-3GalNAc trisaccharide onto the Thr within the VTS motif significantly increases the binding of the MY.1E12 antibody to the MUC1 repeat sequence.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12379325     DOI: 10.1016/s0022-1759(02)00298-3

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  20 in total

1.  Characterization of an immunodominant cancer-specific O-glycopeptide epitope in murine podoplanin (OTS8).

Authors:  Catharina Steentoft; Katrine T Schjoldager; Emiliano Cló; Ulla Mandel; Steven B Levery; Johannes W Pedersen; Knud Jensen; Ola Blixt; Henrik Clausen
Journal:  Glycoconj J       Date:  2010-08-19       Impact factor: 2.916

2.  Assessment of tumor characteristics based on glycoform analysis of membrane-tethered MUC1.

Authors:  Atsushi Matsuda; Michiyo Higashi; Tomomi Nakagawa; Seiya Yokoyama; Atsushi Kuno; Suguru Yonezawa; Hisashi Narimatsu
Journal:  Lab Invest       Date:  2017-06-05       Impact factor: 5.662

3.  Expression of MUC1 recognized by a monoclonal antibody MY.1E12 is a useful biomarker for tumor aggressiveness of carcinoma of the gallbladder.

Authors:  Toru Kawamoto; Junichi Shoda; Naoki Miyahara; Hideo Suzuki; Masato Furukawa; Takeshi Todoroki; Naomi Tanaka; Tatsuro Irimura
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

4.  Expression of MUC1 recognized by monoclonal antibody MY.1E12 is a useful biomarker for tumor aggressiveness of advanced colon carcinoma.

Authors:  Hideo Suzuki; Junichi Shoda; Toru Kawamoto; Eiji Shinozaki; Naoki Miyahara; Souichi Hotta; Yasushi Iizuka; Akira Nakahara; Naomi Tanaka; Akinori Yanaka; Tatsuro Irimura
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

5.  Monoclonal antibodies AC-43 and AC-29 disrupt Plasmodium vivax development in the Indian malaria vector Anopheles culicifacies (Diptera: Culicidae).

Authors:  Manoj Chugh; B R Gulati; S K Gakhar
Journal:  J Biosci       Date:  2010-03       Impact factor: 1.826

6.  A strategy for generating cancer-specific monoclonal antibodies to aberrant O-glycoproteins: identification of a novel dysadherin-Tn antibody.

Authors:  Catharina Steentoft; Max Fuhrmann; Federico Battisti; Julie Van Coillie; Thomas D Madsen; Diana Campos; Adnan Halim; Sergey Y Vakhrushev; Hiren J Joshi; Hans Schreiber; Ulla Mandel; Yoshiki Narimatsu
Journal:  Glycobiology       Date:  2019-04-01       Impact factor: 4.313

7.  Characterization of cancer associated mucin type O-glycans using the exchange sialylation properties of mammalian sialyltransferase ST3Gal-II.

Authors:  E V Chandrasekaran; Jun Xue; Jie Xia; Robert D Locke; Shilpa A Patil; Sriram Neelamegham; Khushi L Matta
Journal:  J Proteome Res       Date:  2012-02-29       Impact factor: 4.466

8.  Monoclonal antibody MG96 completely blocks Plasmodium yoelii development in Anopheles stephensi.

Authors:  Rhoel R Dinglasan; Iesha Fields; Mohammed Shahabuddin; Abdu F Azad; John B Sacci
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

9.  Mucin expression in pleomorphic adenoma of salivary gland: a potential role for MUC1 as a marker to predict recurrence.

Authors:  T Hamada; S Matsukita; M Goto; S Kitajima; S K Batra; T Irimura; K Sueyoshi; K Sugihara; S Yonezawa
Journal:  J Clin Pathol       Date:  2004-08       Impact factor: 3.411

Review 10.  Clinicopathological utility of sialoglycoconjugates in diagnosing and treating colorectal cancer.

Authors:  Yoshinori Inagaki; Jianjun Gao; Peipei Song; Norihiro Kokudo; Munehiro Nakata; Wei Tang
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.